Cutter Capital Management LP Takes $2.46 Million Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Cutter Capital Management LP acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 147,076 shares of the company's stock, valued at approximately $2,464,000. Centessa Pharmaceuticals makes up approximately 1.0% of Cutter Capital Management LP's portfolio, making the stock its 20th biggest position. Cutter Capital Management LP owned 0.11% of Centessa Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after acquiring an additional 660 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares during the period. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after buying an additional 5,316 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after purchasing an additional 6,000 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CNTA has been the subject of several research analyst reports. Guggenheim restated a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Oppenheimer began coverage on Centessa Pharmaceuticals in a research note on Thursday. They set an "outperform" rating and a $6.00 target price for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Chardan Capital assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday. They issued a "buy" rating and a $30.00 price objective for the company. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $27.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded down $0.10 during trading hours on Friday, reaching $12.29. The stock had a trading volume of 509,977 shares, compared to its average volume of 626,589. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -8.03 and a beta of 1.53. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The firm has a 50-day moving average of $13.86 and a 200-day moving average of $15.67. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. Equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 2,080 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the transaction, the general counsel now directly owns 105,386 shares in the company, valued at approximately $1,476,457.86. This represents a 1.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the sale, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. The trade was a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 171,827 shares of company stock valued at $2,705,568 over the last ninety days. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.